EX-10.1 2 y34395exv10w1.htm EX-10.1: NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENTNon-Exclusive License and Material Transfer Agreement • May 5th, 2020 • New York
Contract Type FiledMay 5th, 2020 JurisdictionExhibit 10.1 NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENT This Non-Exclusive License and Material Transfer Agreement (“Agreement”) is entered into with an effective date as of March 30, 2007 (the “Effective Date”), by and between Astellas Pharma Inc., a Japanese company with a principal place of business located at 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“Company”), and Regeneron Pharmaceuticals, Inc. (“Regeneron”), a New York corporation, with a principal place of business located at 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707. WITNESSETH WHEREAS, Regeneron has developed antibody technology, including genetically modified mice and related know-how, useful to generate human monoclonal antibodies; WHEREAS, Regeneron owns certain patents and patent applications covering its human antibody technology; WHEREAS, Company desires to obtain certain non-exclusive licenses under Regeneron Technology (as defined below), including the right to commerciali
PLEASE READ THIS NON-EXCLUSIVE LICENSE AGREEMENT AND MATERIAL TRANSFER AGREEMENT BEFORE USING THE ENCLOSED MATERIAL. UPON REMOVAL OF THE MATERIAL FROM THIS PACKAGE, RECIPIENT AGREES TO ALL THE TERMS OF THIS NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER...Non-Exclusive License and Material Transfer Agreement • June 18th, 2021
Contract Type FiledJune 18th, 2021
Amendment to the Non-Exclusive License and Material Transfer Agreement dated as of March 30, 2007Non-Exclusive License and Material Transfer Agreement • October 28th, 2010 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledOctober 28th, 2010 Company Industry JurisdictionThis Amendment (“Amendment”), dated as of July 28, 2010 (the “Amendment Effective Date”), is by and between Astellas Pharma Inc. (“Company”), a Japanese company with a principal place of business located at 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan and Regeneron Pharmaceuticals, Inc. (“Regeneron”), a New York corporation with its principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591.
NON-EXCLUSIVE LICENSE AND MATERIAL TRANSFER AGREEMENTNon-Exclusive License and Material Transfer Agreement • April 17th, 2023 • New York
Contract Type FiledApril 17th, 2023 JurisdictionThis Non-Exclusive License and Material Transfer Agreement (“Agreement”) is entered into with an effective date as of March 30, 2007 (the “Effective Date”), by and between Astellas Pharma Inc., a Japanese company with a principal place of business located at 2-3-11 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan (“Company”), and Regeneron Pharmaceuticals, Inc. (“Regeneron”), a New York corporation, with a principal place of business located at 777 Old Saw Mill River Road, Tarrytown, New York 10591-6707.
WITNESSETHNon-Exclusive License and Material Transfer Agreement • March 12th, 2007 • Regeneron Pharmaceuticals Inc • Pharmaceutical preparations • New York
Contract Type FiledMarch 12th, 2007 Company Industry Jurisdiction